title: Clinical comparision of intravesical hyaluronic acid and hyaluronic acid-chondroitin sulphate therapy for patients with bladder pain syndrome/interstitital cystitis.
abstract: BACKGROUND
  Patients with a history of bladder pain syndrome/interstitial cystitis (BPS/IC) and who responded poorly or unsatisfactorily with previous treatment were compared taking intravesical hyaluronic acid (HA) or hyaluronic acid-chondroitin sulphate (HA-CS).
  
  
  METHODS
  Patients were treated with intravesical instillation with 50 mL sterile sodium hyalurinic acid (Hyacyst, Syner-Med, Surrey, UK) (n = 32) and sodium hyaluronate 1.6% sodium chondroitin sulphate 2% (Ialuril, Aspire Pharma, UK) (n = 33). Intravesical instillations were performed weekly in first month, every 15 days in the second month and monthly in third and fourth months, for a total of 8 doses. Patients were evaluated using a visual analog pain scale (VAS), interstitial cystitis symptom index (ICSI), interstitial cystitis problem index (ICPI), voiding diary for frequency/nocturia, cystometric bladder capacity and voided volume at the beginning and at 6 months. All patients had a potassium sensitivity test (PST) initially. Wilcoxon and Mann-Whitney U tests were used for statistical analysis.
  
  
  RESULTS
  In total, 53 patients met the study criteria. There were 30 patients in the HA-CS group (mean age: 48.47) and 23 patients in the HA group (mean age: 49.61) (p > 0.05). The initial PST was positive in 71.7% patients (38/53) overall with no difference between groups (p > 0.05). Responses for VAS, ICCS, ICPS, 24-hour frequency/nocturia statistically improved in both groups at 6 months. There was no significant difference in symptomatic improvement (p > 0.05). Eight patients had mild adverse events.
  
  
  CONCLUSIONS
  HA and HA/CS instillation can be effective in BPS/IC patients who do not respond to conservative treatment. An important limitation of our study is that the HA dosage of the 2 treatment arms were different. It would be more appropriate with same HA dosage in both groups; however, there was no commercially available glycosaminoglycan (GAG) substance with same HA dosage for single and combination therapy. Large, long-term randomized studies are required to determine if there is a difference between these treatments.
authors.affiliation: Department of Urology, Ankara University, Ankara, Turkey.
authors.forename: Omer
authors.initials: O
authors.lastname: Gülpınar
authors.affiliation: Department of Urology, Ankara University, Ankara, Turkey.
authors.forename: Aytaç
authors.initials: A
authors.lastname: Kayış
authors.affiliation: Department of Urology, Ankara University, Ankara, Turkey.
authors.forename: Evren
authors.initials: E
authors.lastname: Süer
authors.affiliation: Department of Urology, Ankara University, Ankara, Turkey.
authors.forename: Mehmet İlker
authors.initials: Mİ
authors.lastname: Gökçe
authors.affiliation: Department of Urology, Ankara University, Ankara, Turkey.
authors.forename: Adil Güçal
authors.initials: AG
authors.lastname: Güçlü
authors.affiliation: Department of Urology, Ankara University, Ankara, Turkey.
authors.forename: Nihat
authors.initials: N
authors.lastname: Arıkan